FDA Issues CRL for Bevacizumab Used for Wet AMD
Written by
American Journal Managed Care
Published
0
comments
0
min
This marks the second complete response letter (CRL) received by Outlook Therapeutics for its treatment targeting wet age-related macular degeneration (AMD).